A5087484194- Systemic Lupus Erythematosus Research
- Vasculitis and related conditions
- Otitis Media and Relapsing Polychondritis
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Systemic Sclerosis and Related Diseases
- Atherosclerosis and Cardiovascular Diseases
- Rheumatoid Arthritis Research and Therapies
- Eosinophilic Disorders and Syndromes
- Urticaria and Related Conditions
- Immunodeficiency and Autoimmune Disorders
- Pulmonary Hypertension Research and Treatments
- Sarcoidosis and Beryllium Toxicity Research
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Musculoskeletal Disorders and Rehabilitation
- Pregnancy and preeclampsia studies
- Renal Diseases and Glomerulopathies
- Hepatitis Viruses Studies and Epidemiology
- Inflammatory Bowel Disease
- Psoriasis: Treatment and Pathogenesis
- Medical and Biological Sciences
- Glutathione Transferases and Polymorphisms
- Reproductive System and Pregnancy
- Lipoproteins and Cardiovascular Health
- Parvovirus B19 Infection Studies
- Spondyloarthritis Studies and Treatments
Hospital Arnau de Vilanova
2016-2021
Marqués de Valdecilla University Hospital
2019
Instituto de Investigación Sanitaria La Fe
2019
American College of Rheumatology
2019
Hospital Universitario Doctor Peset
2006-2007
Center for Rheumatology
2006
Objective: To assess the efficacy and safety of tocilizumab (TCZ) in Caucasian patients with refractory Takayasu’s arteritis (TAK) clinical practice. Methods: A multicenter study TAK who received TCZ. The outcome variables were remission, glucocorticoid-sparing effect, improvement imaging techniques, adverse events. comparative between TCZ as monotherapy (TCZ MONO ) combined conventional disease modifying anti-rheumatic drugs (cDMARDs) COMBO was performed. Results: comprised 54 (46 women/8...
ABSTRACTBackground: Bosentan, an oral dual endothelin receptor antagonist, has shown to be effective in the treatment of pulmonary arterial hypertension (PAH) and ischaemic digital ulcers (IDU) systemic sclerosis (SSc) patients. Some clinical reports also suggest a short-term benefit treating Raynaud's phenomenon cutaneous fibrosis (CF) SSc The aim this case series was describe long-term bosentan CF.Methods: In open, non-controlled prospective series, patients were treated with (mean...
<h3>Background</h3> Giant cell arteritis (GCA) is a large-vessel vasculitis which can involve the aorta and/or its major branches. Tocilizumab (TCZ) seems to be effective in giant (GCA).<sup>1–4</sup> <h3>Objectives</h3> Our aim was assess if clinical and analytical improvement yielded patients with GCA treated TCZ accompanied by reduction of vascular inflammation evaluated PET/CT. <h3>Methods</h3> Study 36 who had baseline follow-up PET/CT from multicenter series 134 treatment TCZ. The...
<h3>Background</h3> Giant cell arteritis (GCA) can be refractory to corticosteroid therapy. Tocilizumab (TCZ) has been approved in the treatment of GCA. There are no studies comparing efficacy and safety when using TCZ as monotherapy or combination with conventional immunosuppressive drugs <h3>Objectives</h3> Our aim was compare combined <h3>Methods</h3> Multicenter study on 134 patients GCA who received therapy immunosuppressants. Prolonged remission, absence clinical symptoms signs...
<h3>Background</h3> Giant cell arteritis (GCA) is a large vessel vasculitis with predisposition for the cranial branches of external carotid artery. However, aorta and/or its main may also be involved. <h3>Objectives</h3> In series patients GCA who presented extracranial involvement, our aim was to assess <b>a)</b> vascular territories most frequently affected and <b>b)</b> correlation major extension involvement more severe clinical analytical features. <h3>Methods</h3> Multicenter study 68...
<h3>Background</h3> Systemic lupus erythematous (SLE) is an autoimmune disease characterised by deregulation of cytokine production. INF1A a proinflamatory considered as key molecule in the SLE etiopathogenesis, being responsible indirectly IL10 upregulation. BLyS involved autoantibodies production and clinical activity SLE, its expression regulated other cytokines INF1A. IL2 anti-inflammatory but loss leads to Th2 proinflammatory IL4, IL5 IL13. <h3>Objectives</h3> To analyse association...
<h3>Background</h3> Giant cell arteritis (GCA) is a large vessel vasculitis with predisposition for the cranial branches of external carotid artery. However, aorta and/or its main may also be involved <b>(<sup>1–3</sup></b>. <h3>Objectives</h3> To assess vascular territories most frequently affected in series patients GCA who presented extracranial involvement. <h3>Methods</h3> Retrospective study compromise vessels confirmed by PET/CT. Visual analysis uptake was performed on supra-aortic...
Background: Tocilizumab (TCZ) is the only biological agent approved in Giant Cell Arteritis (GCA). There general agreement on initial and standard maintenance dose of TCZ. However, information duration optimization TCZ GCA scarce. Objectives: Our aim was to assess efficacy safety therapy an unselected wide series clinical practice. Methods: Multicenter study, 134 patients with who received due inefficacy/adverse events previous therapy. Once complete remission reached based a shared decision...
<h3>Background</h3> In the latest study published by SEOM (Spanish Society of Medical Oncology) in 2012, most prevalent types cancers Spanish women are breast, colorectal, corpus uteri, lung and ovary. addition, Systemic Lupus Erythematosus (SLE) patients a higher incidence cancer has been described, about 15–20% higher. Today, there is some controversy around activity on SLE or even drugs employed such as cyclophosphamide could be an extra risk factor for development these patients. fact,...
<h3>Background</h3> According to clinical guidelines, treatment with a DMARD should be initiated as soon possible, and any patient who does not improve at least one relevant synthetic is candidate for biological one. However, up third of the patients treated do accomplish therapeutic objective. <h3>Objectives</h3> To identify assess attributes DMARDs which determine most suitable RA. <h3>Methods</h3> We performed systematic search following MeSH terms: rheumatoid arthritis, biologic, DMARD,...
<h3>Background</h3> Oxidative stress is increased in Systemic Lupus Erythematosus (SLE) patients, and contributes to the immune system imbalance, abnormal activation of apoptotic processes, autoantibodies production development serious complications, such as cardiovascular comorbidities. <h3>Objectives</h3> To evaluate influence oxidative an additional factor classical risk ones, SLE patients. <h3>Methods</h3> Cross-sectional prospective study patients according SLICC-2012 criteria, coming...
<h3>Background</h3> Systemic Lupus Erythematosus (SLE) in a multisystemic and autoimmune disease that specially affects young women during the second third decade, is able to injure different organs or systems, being most common one affected musculoskeletal system. Events attributed SLE itself other related may impact negatively quality of life, unemployment, disability mortality. Recent data show 3.8% patients have comorbidities 59.2% them were receiving pension. In Spain, evaluation...
<h3>Background</h3> Systemic Lupus Erythematosus (SLE) in a multisystemic autoimmune disease that specially affects young women during the second and third decade, is able to injure different organs or systems, being most common one affected musculoskeletal system. <h3>Objectives</h3> To analyse influence of time evolution age patient current clinical manifestations debut patients with SLE. <h3>Methods</h3> Cross-sectional prospective study SLE according SLICC-2012 criteria, coming from...
<h3>Background</h3> The late-onset Systemic Lupus Erithematosus (SLE) has been defined as that one beginning after 50 years old, and supposes around 6–18% of the SLE patients. According to literature, most common clinical manifestations are interstitial lung disease, serositis, Sjögren9s syndrome cytopenias. Though illness activity is lower in these patients, this population usually stands with more accumulative damage a higher mortality than early-onset <h3>Objectives</h3> To study...
<h3>Background</h3> The first cause of mortality in patients with Systemic Lupus Erythematosus (SLE) is cardiovascular disease (CVD). Accelerated atherosclerosis that occurs SLE considered one the fundamental mechanisms increase this group patients. Among factors contribute to accelerated process, we include classical CVD risk factors, as well inflammatory and specific factors. <h3>Objectives</h3> To assess CVR possibility modifying it based on accumulative damage activity. <h3>Methods</h3>...
<h3>Background</h3> Systemic lupus erythematous (SLE) is an autoimmune disease characterized by immune system disruption with autoantibodies production. One of the upregulated specific to Ro antigen, a ribonucleoprotein associated small RNA, constituted 52KDa and 60 KDa polypeptides, whose epitopes are mainly conformational. The routine detection method for anti-Ro enzyme immunoassay, however, possible obtain false-negatives this could be avoided analyzing both subunits separately....
<h3>Background</h3> Systemic lupus erythematous (SLE) is an autoimmune disease characterized by immune system disruption, including T and B cell activation upregulation of autoantibody immunocomplexes production that could damage different organs. Sometimes, patients with positives autoantibodies serological manifestations show low activity or clinical remission. There not enough information about persistent positive in absence neither the role proinflamatory cytokines this context....
<h3>Background</h3> Systemic lupus erythematous (SLE) is an autoimmune disease characterized by immune system disruption, including deregulation of cytokine production. Interferon alpha (INF1A) considered a key molecule in SLE etiopathogenesis, being responsible the differentiation dendritic cells from monocytes, and indirectly interleukin 10 (IL10) upregulation. The B lymphocyte stimulating factor (BLyS) involved autoantibodies production clinical activity, regulated other cytokines as IL10...
<h3>Background</h3> B lymphocyte stimulator factor (BLyS) is produced by wide range of cells the immune system, and has proven to be a key in selection survival cells. BLyS an important pathology Systemic Lupus Erythematosus; elevated serum levels (≥20ng/mL) soluble BlyS are at increased risk flare. <h3>Objectives</h3> Analyze association among clinical manifestations, as well with SLE activity. <h3>Methods</h3> A cross-sectional observational study was performed patients diagnosed according...